ABSTRACT
Aortic dimensions and distensibility are key risk factors for aortic aneurysms and dissections, as well as for other cardiovascular and cerebrovascular diseases. We tested genome-wide associations of ascending and descending aortic distensibility and area derived from cardiac magnetic resonance imaging (MRI) data of up to 32,590 Caucasian individuals in UK Biobank. We identified 102 loci (including 31 novel associations) tagging genes related to cardiovascular development, extracellular matrix production, smooth muscle cell contraction and heritable aortic diseases. Functional analyses highlighted four signalling pathways associated with aortic distensibility (TGF-β, IGF, VEGF and PDGF). We identified distinct sex-specific associations with aortic traits. We developed co-expression networks associated with aortic traits and applied phenome-wide Mendelian randomization (MR-PheWAS), generating evidence for a causal role for aortic distensibility in development of aortic aneurysms. Multivariable MR suggested a causal relationship between aortic distensibility and cerebral white matter hyperintensities, mechanistically linking aortic traits and brain small vessel disease.
Competing Interest Statement
PMM acknowledges consultancy fees from Novartis, Bristol Myers Squibb, Celgene and Biogen. He has received honoraria or speakers honoraria from Novartis, Biogen and Roche and has received research or educational funds from Biogen, Novartis, GlaxoSmithKline and Nodthera.
Funding Statement
PMM acknowledges generous personal and research support from the Edmond J Safra Foundation and Lily Safra, a National Institute for Health Research (NIHR) Senior Investigator Award, the UK Dementia Research Institute and the NIHR Biomedical Research Centre at Imperial College London. CF acknowledges generous support from the BHF Imperial Centre of Research Excellence RE/18/4/34215. This research has been conducted using the UK Biobank Resource under Application Number 18545. PE is director of the Medical Research Council (MRC) Centre for Environment and Health and acknowledges support from the MRC (MR/L01341X/1; MR/ S019669/1). PE is director of the Health Protection Research Unit in Chemical and Radiation Threats and Hazards, funded by the NIHR. PE also acknowledges support from the NIHR Imperial Biomedical Research Centre, the Imperial College British Heart Foundation Centre for Research Excellence (RE/18/4/34215), the UK Dementia Research Institute at Imperial College London (MC_PC_17114), and Health Data Research UK for London. SD is supported by a grant overseen by the French National Research Agency (ANR) as part of the Investment for the Future Programme ANR-18- RHUS-002 and by the ERC and the EU H2020 under grant agreements 640643, 667375, and 754517. The CADISP study has been supported by Inserm, Lille 2 University, Institut Pasteur de Lille and Lille University Hospital and received funding from the ERDF (FEDER funds) and Région Nord-Pas de Calais in the frame of Contrat de Projets Etat-Region 2007-2013 Région Nord-Pas-de-Calais - Grant No 09120030, Centre National de Genotypage, Emil Aaltonen Foundation, Paavo Ilmari Ahvenainen Foundation, Helsinki University Central Hospital Research Fund, Helsinki University Medical Foundation, Päivikki and Sakari Sohlberg Foundation, Aarne Koskelo Foundation, Maire Taponen Foundation, Aarne and Aili Turunen Foundation, Lilly Foundation, Alfred Kordelin Foundation, Finnish Medical Foundation, Orion Farmos Research Foundation, Maud Kuistila Foundation, the Finnish Brain Foundation, Biomedicum Helsinki Foundation, Projet Hospitalier de Recherche Clinique Régional, Fondation de France, Génopôle de Lille, Adrinord, Basel Stroke-Funds, Käthe-Zingg-Schwichtenberg-Fonds of the Swiss Academy of Medical Sciences, Swiss Heart Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC), which covers the UK. In Scotland, UK Biobank has approval from the Community Health Index Advisory Group (CHIAG).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* joint first authors
Data Availability
Summary statistics for all GWAS analyses are available upon request.
